INGELHEIM, Germany and HØRSHOLM, Denmark – September 7, 2017 Obesity affects more than half a billion people worldwide and is a leading risk factor for some of the biggest global drivers of morbidity and mortality, such as heart disease, stroke…
Hørsholm, August 30, 2017 Today, Gubra announced the successful conclusion of a research collaboration with Sanofi, focusing on the discovery of novel gastrointestinal peptides that could potentially lead to the development of drugs for the treatment of diabetes and obesity.…
June 1, 2016 Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has…
Hørsholm, September 23, 2013 Gubra today announced the launch of a new research collaboration agreement with Sanofi focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people…